Corline Biomedical (Q2 Review): Early stages of the Globe ramp-up - Redeye

Redeye provides an update following Corline’s Q2 2026 report. Sales came in below expectations, while cost control remains solid. We do not draw any major conclusions from the lower-than-expected sales and continue to see a strong long-term outlook. In this research update, we make some adjustments to our short-term sales estimates and introduce a new fair value, which suggests that the Corline share is currently attractively priced.

Länk till analysen i sin helhet: https://www.redeye.se/research/1181928/corline-biomedical-q2-review-early-stages-of-the-globe-ramp-up?utm_source=finwire&utm_medium=RSS